KPIs & Operating Metrics(New)

Balance Sheet

Cash Flow Statement

Acquisitions Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Discontinued Operations Cash from Discontinued Operations Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Dividends Paid - Common Dividends Paid - Common Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances

Daily Values

Growth Metrics

Merck (MRK) Capital Expenditures (2016 - 2026)

Merck has reported Capital Expenditures over the past 18 years, most recently at $991.0 million for Q1 2026.

Quarterly Capital Expenditures fell 25.38% to $991.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $3.8 billion through Mar 2026, down 1.67% year-over-year, with the annual reading at $4.1 billion for FY2025, 21.95% up from the prior year.
Capital Expenditures was $991.0 million for Q1 2026 at Merck, down from $1.0 billion in the prior quarter.
Over five years, Capital Expenditures peaked at $1.3 billion in Q1 2025 and troughed at $764.0 million in Q2 2025.
The 5-year median for Capital Expenditures is $987.0 million (2025), against an average of $983.9 million.
Year-over-year, Capital Expenditures skyrocketed 54.24% in 2025 and then fell 25.38% in 2026.
A 5-year view of Capital Expenditures shows it stood at $1.1 billion in 2022, then decreased by 13.93% to $989.0 million in 2023, then dropped by 5.26% to $937.0 million in 2024, then grew by 10.25% to $1.0 billion in 2025, then decreased by 4.07% to $991.0 million in 2026.
Per Business Quant, the three most recent readings for MRK's Capital Expenditures are $991.0 million (Q1 2026), $1.0 billion (Q4 2025), and $987.0 million (Q3 2025).